
## Seoul International Digestive Disease Symposium 2025



April 19-20, 2025 | Swiss Grand Hotel Seoul, Korea

Frontiers in Digestive Research and Practice



SIDDS 2021

Name	Min Kyung Park
Affiliation	Seoul National University Bundang Hospital
Country	South Korea
Major Field	Hepatology

## **Educational Background**

- 2021 2023 Seoul National University, College of Medicine PhD., Stem Cell Biology
- 2013 2017 Seoul National University, College of Medicine M.D. Master Degree of medicine
- 2008 2012 **Seoul National University** B.S., Biology (*Major*), Economics (*Minor*)

## **Professional Experience**

- 2017 2018 Medical Internship, Seoul National University Hospital
- 2018 2021 **Residency in Internal Medicine**, Seoul National University Hospital
- 2018 2022 Research and Clinical Fellow, Seoul National University Hospital
- 2022 2023 Clinical Assistant Professor, Seoul National University Hospital
- 2023 Clinical Assistant Professor, Seoul National University Bundang Hospital

## **Main Scientific Publications**

- 1. <u>Park MK</u>\*, Hur MH\*, Moon HS\*, et al. Extrahepatic malignancies in metabolic dysfunction-associated fatty liver disease: A nationwide cohort study. *Liver Int*. Published online January 17, 2024. (\* co-first authors)
- 2. <u>Park MK</u>\*, Lee DH\*, Hur BY, et al. Effectiveness of US Surveillance of Hepatocellular Carcinoma in Chronic Hepatitis B: US LI-RADS Visualization Score. *Radiology*. 2023;307(5):e222106. (\* co-first authors)
- 3. Hur MH\*, <u>Park MK</u>\*, Cheuk-Fung Yip T\*, Chen CH\*, Lee HC\*, Choi WM\*, et al. Personalized antiviral drug selection in chronic hepatitis B patients using a machine learning model: a multinational study. [published online ahead of print, 2023 Mar 7]. *Am J Gastroenterol*. (\* co-first authors)
- 4. Chung SW\*, <u>Park MK</u>\*, Cho YY\*, et al. Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. *J Hepatocell Carcinoma*. 2021;8:587-598. Published 2021 Jun 15. (\* co-first authors)
- 5. <u>Park MK</u>, Lee YB, Moon H, Choi NR, Kim MA, Jang H, Nam JY, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH. Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation. *Dig Dis Sci.* 2022 Jan 20. (First authors)
- 6. <u>Park MK</u>, YB Lee. Diagnosis and Management of Esophageal and Gastric Variceal Bleeding: Focused on 2019 KASL Clinical Practice Guidelines for Liver Cirrhosis. *Korean J Gastroenterol* 2021; 78(3): 152-160. Published 2021 Sep 25. (First authors)
- 7. <u>Park MK</u>, Yu SJ. Concurrent transarterial radioembolization and combination atezolizumab/bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report. *Journal of Liver Cancer*. 2022; 22(1) 69-74. (First authors)
- 8. <u>Park MK</u>, Kim YJ. What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea? *Clin Mol Hepatol*. 2023;29(2):332-334. (First authors)